Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (Nasdaq: RVMD) generates frequent news as a late-stage clinical oncology company advancing a pipeline of RAS(ON) inhibitors for RAS-addicted cancers. Its public announcements highlight clinical trial milestones, regulatory designations and corporate developments related to drug candidates such as daraxonrasib, elironrasib and zoldonrasib.
News coverage for RVMD often centers on clinical data readouts and trial progress. The company has reported results from studies of daraxonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC) in both previously treated and first-line settings, as well as combination regimens with gemcitabine and nab-paclitaxel. It also releases updates on global Phase 3 trials, including RASolute 302 and 304 in PDAC and RASolve 301 in RAS-mutant non-small cell lung cancer (NSCLC).
Another key news theme is regulatory interaction with the U.S. Food and Drug Administration. Revolution Medicines has announced FDA Breakthrough Therapy Designations for daraxonrasib, elironrasib and zoldonrasib in specific KRAS-mutant NSCLC and pancreatic cancer settings, Orphan Drug Designation for daraxonrasib in pancreatic cancer, and a Commissioner’s National Priority Voucher for daraxonrasib. These items are frequently covered in press releases and investor communications.
Investors and observers can also expect corporate and financial updates, including quarterly financial results, strategic financing transactions such as the Royalty Purchase Agreement with Royalty Pharma, and leadership appointments to support late-stage development and potential commercialization. Conference presentations at major healthcare and oncology meetings, where the company shares updated clinical and preclinical data, are another recurring source of news.
This news page aggregates such disclosures, offering a centralized view of Revolution Medicines’ clinical progress, regulatory milestones and corporate events for those tracking RVMD’s development in RAS-driven oncology.
Revolution Medicines (Nasdaq: RVMD) will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference from June 8-11, 2021. CEO Mark A. Goldsmith will engage in a fireside chat on June 9, 2021, at 3:00 p.m. Eastern Time. Interested individuals can access the live webcast through the events page on Revolution Medicines’ website, with a replay available for 14 days post-conference. The company focuses on precision oncology, developing targeted therapies for RAS-addicted cancers, including RMC-6291 and RMC-6236.
Revolution Medicines (Nasdaq: RVMD), a precision oncology company, will participate in the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20-21, 2021. Steve Kelsey, M.D., will present in a fireside chat on May 21 at 12:40 p.m. Eastern. The company focuses on developing targeted therapies for RAS-addicted cancers, with a pipeline including RAS(ON) Inhibitors like RMC-6291 and RMC-6236, and RAS Companion Inhibitors such as RMC-4630. Revolution Medicines leverages advanced drug discovery methods to create innovative small molecules aimed at treating challenging cancer variants.
Revolution Medicines (Nasdaq: RVMD) reported a net loss of $37.2 million for Q1 2021, up from $19.5 million a year earlier. Revenue fell to $10.1 million, compared to $11.5 million in Q1 2020. R&D expenses rose to $40.9 million due to increased research and personnel costs. The company raised $281 million through a public offering to support its clinical pipeline. RMC-6291 and RMC-6236, two RAS(ON) inhibitors, are undergoing IND-enabling development, with both expected to submit IND applications in H1 2022. The company anticipates a full-year net loss between $170 million and $190 million.
Revolution Medicines, a precision oncology company (Nasdaq: RVMD), announced the nomination of Flavia Borellini, Ph.D., for election to its board of directors as a Class I director. She joins current nominees Elizabeth McKee Anderson and Neil Exter for reelection at the annual stockholder meeting on June 22, 2021. Dr. Borellini has over 25 years of leadership in oncology drug development, previously serving as CEO of Acerta Pharma and holding key roles at AstraZeneca and Genentech. The nomination aims to strengthen the board's expertise in targeted therapy development for RAS-addicted cancers.
Revolution Medicines announced the initiation of a multicenter Phase 1/1b clinical trial for RMC-5552, a first-in-class bi-steric mTORC1 inhibitor targeting relapsed/refractory solid tumors. The trial aims to assess the drug's safety, tolerability, and preliminary efficacy. Additionally, the U.S. Patent Office issued Patent No. 10,980,889, providing composition protection for RMC-5552 and related compounds. This advancement aligns with the company's focus on developing therapies for RAS-addicted cancers, crucial given the biological complexities of these tumors.
Revolution Medicines (Nasdaq: RVMD) announced six presentations at the AACR Annual Meeting 2021, scheduled for April 10-15, showcasing advancements in their RAS(ON) Inhibitors and RAS Companion Inhibitors. Notable presentations include the SHP2 inhibitor RMC-4630's anti-tumor activity and the development of first-in-class KRAS G12V inhibitors. The event emphasizes the company's commitment to precision oncology and highlights their ongoing research in treating RAS-addicted cancers.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company, announced participation in two investor conferences. CEO Mark A. Goldsmith will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, from 1:10 to 1:40 p.m. Eastern. Additionally, he will participate in a fireside chat at the J.P. Morgan 10th Annual Napa Valley Forum on March 29, 2021, from 2:00 to 2:45 p.m. Eastern. Revolution Medicines focuses on developing targeted therapies for RAS-addicted cancers, with R&D initiatives around RAS(ON) and Companion Inhibitors.
Revolution Medicines (Nasdaq: RVMD) announced significant advancements in its RAS(ON) inhibitor development, entering IND-enabling stages for two candidates, RMC-6291 and RMC-6236. Both are aimed at addressing RAS-addicted cancers. The company successfully raised $281 million in net proceeds to fund these efforts. However, financial results revealed a decline in revenue, with full-year totals down from $50 million in 2019 to $43 million in 2020. The net loss also increased to $108.2 million in 2020, up from $47.7 million the previous year, with guidance suggesting a further loss of $170 million to $190 million for 2021.
Revolution Medicines (Nasdaq: RVMD) announced participation in the Digital RAS-Targeted Drug Discovery Summit from February 23-25, 2021. Steve Kelsey, M.D., will present on RAS(ON) Inhibitor programs, including RMC-6291 and RMC-6236, which are in IND-enabling development. Kelsey will also join a panel discussion on mechanisms of resistance in combination therapies. Additionally, Revolution Medicines will participate in three upcoming investor conferences, with presentations scheduled for February and March 2021.
Revolution Medicines (Nasdaq:RVMD) announced the closing of a public offering of 6,666,666 shares at $45.00 each, totaling gross proceeds of $300 million. This includes 869,565 additional shares sold after underwriters exercised their option. The offering was managed by J.P. Morgan, Cowen, SVB Leerink, and Guggenheim Securities, with prior SEC registration on February 3, 2021. Funds will support the company’s focus on developing targeted therapies for RAS-addicted cancers.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
